Article
Chemistry, Medicinal
Maryam Zangi, Katherine A. Donald, Andreu Gazquez Casals, Abaigeal D. Franson, Alice J. Yu, Elise M. Marker, Molly E. Woodson, Scott D. Campbell, M. Abdul Mottaleb, Tanguturi Venkata Narayana Hajay Kumar, Makala Shakar Reddy, Lingala Vijaya Raghava Reddy, Subir Kumar Sadhukhan, David W. Griggs, Lynda A. Morrison, Marvin J. Meyers
Summary: The derivative compounds of ciclopirox olamine effectively inhibit replication of HSV-2 with low cytotoxicity, indicating their strong therapeutic potential. Structural comparison confirms the importance of hydrophobic groups in the efficacy of ciclopirox and its derivatives.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Immunology
Shiza Malik, Ranjit Sah, Omar Ahsan, Khalid Muhammad, Yasir Waheed
Summary: Research on herpes simplex virus (HSV) indicates that current antiviral therapies can alleviate symptoms and control viral transmission, but they cannot eradicate HSV infection and latency. The complex nature of the virus requires continued efforts to develop new treatment methods to control its spread and mutations.
Article
Virology
Nabil El Bilali, Bita Khadivjam, Eric Bonneil, Pierre Thibault, Roger Lippe
Summary: The study investigated the composition of HSV-1 A, B, and C nuclear capsids, identifying host proteins specific to C-capsids. By purifying viral particles using a novel method, it aims to uncover the differences and functional relevance of these viral capsids. This innovative approach opens up new research avenues to clarify the biology of herpesviruses.
JOURNAL OF VIROLOGY
(2021)
Review
Immunology
Iara M. M. Backes, David A. A. Leib, Margaret E. E. Ackerman
Summary: The fetal/neonatal period is a critical stage for interventions and also a vulnerable period for viral infections. Maternal transfer of antibodies can reduce the risk of neonatal herpes simplex virus (nHSV) infections. Exploring the combination of antibody-based interventions and antiviral therapy is important for reducing infant mortality and long-term morbidity.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Virology
Domenico Umberto De Rose, Sarah Bompard, Chiara Maddaloni, Iliana Bersani, Ludovica Martini, Alessandra Santisi, Daniela Longo, Maria Paola Ronchetti, Andrea Dotta, Cinzia Auriti
Summary: This review examines recent literature on the management of herpes simplex virus infections in neonates, summarizing the clinical categories of maternal HSV infection during pregnancy and the mechanisms of fetal damage. The article also distinguishes the types and presentations of neonatal infection, and emphasizes the importance of tailored acyclovir treatment and multidisciplinary follow-up. It highlights the challenges in prevention strategies in the absence of an available HSV vaccine.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Review
Virology
Joshua D. Bernstock, Samantha E. Hoffman, Jason A. Chen, Saksham Gupta, Ari D. Kappel, Timothy R. Smith, E. Antonio Chiocca
Summary: Despite advances in surgical resection and chemoradiation, high-grade brain tumors remain associated with significant morbidity/mortality, necessitating novel therapeutic strategies. Immunotherapy and immunovirotherapy are among the forefront of these new approaches being investigated for incurable brain tumors. This mini review focuses on oncolytic herpes viruses (oHSV) currently in clinical trials.
Article
Immunology
Meng-Shan Tsai, Shun-Hua Chen, Chih-Peng Chang, Yi-Ling Hsiao, Li-Chiu Wang
Summary: ILK reduces the accumulation of H3K9me3 on HSV-1 DNA by reducing SUV39H1 and TRIM28 binding, enhancing virus replication. ILK knockdown decreases TRIM28 phosphorylation, weakening its inhibition on lytic gene transcription. ILK inhibitor suppresses HSV-1 replication.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Microbiology
Tony Elias, Lee H. Lee, Miriam Rossi, Francesco Caruso, Sandra D. Adams
Summary: Embelin shows noncytotoxicity at tested concentrations and inhibits HSV-1 infection in Vero cells by affecting the early stages of viral attachment and penetration. Additionally, embelin reduces oxidative damage caused by HSV-1 infection, making it an effective antiviral agent in cultured cells. Further research is needed to explore the potential of embelin as a medicinal treatment.
Article
Microbiology
Yuko Sato, Tadahiro Suenaga, Makoto Kobayashi, Nozomu Miyazaki, Takato Suzuki, Ken Ishioka, Tatsuo Suzutani
Summary: This study identified AMNV-resistant HSV-1 and HSV-2 viruses with amino acid substitutions in UL5 and UL52, downstream of motif IV. The most frequent mutations were UL5 K356N in HSV-1 and K355N in HSV-2. Recombinant viruses with single amino acid substitutions showed various levels of AMNV resistance, with UL5 K356N mutant maintaining equivalent viral growth and virulence as the parent virus.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Immunology
Nelly R. Mugo, Randy M. Stalter, Renee Heffron, Helen Rees, Caitlin W. Scoville, Charles Morrison, Athena P. Kourtis, Elizabeth Bukusi, Mags Beksinka, Neena M. Philip, Ivana Beesham, Jen Deese, Vinodh Edward, Deborah Donnell, Jared M. Baeten
Summary: This study found no association between HSV-2 acquisition and the use of three contraceptive methods through a randomized trial. Previous observational studies have suggested a possible association between the use of intramuscular depot medroxyprogesterone acetate (DMPA-IM) and HSV-2 acquisition.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Chemistry, Medicinal
Kai Jiang, Jing Feng, Xia Qi, Lili Ran, Lixin Xie
Summary: This study validated the inhibitory effect of oridonin on herpes simplex virus type 1 and demonstrated its potential in alleviating herpes simplex keratitis infection in mice.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Review
Immunology
Christine Johnston
Summary: This article discusses the management of genital herpes infection and provides recommendations based on a systematic literature review, serving as a basis for updating the treatment guidelines.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Chemistry, Medicinal
Christian Gege, Gerald Kleymann
Summary: Helicase-primase is an interesting target for therapy of herpes simplex virus infections. Multiple drug candidates have been developed and approved. This article describes the patent portfolio of helicase-primase inhibitors from Phaeno Therapeutics and proposes the structure of their drug candidate HN0037.
EXPERT OPINION ON THERAPEUTIC PATENTS
(2022)
Article
Pharmacology & Pharmacy
Hiroki Kondo, Tetsuo Koshizuka, Ryuichi Majima, Keita Takahashi, Ken Ishioka, Tatsuo Suzutani, Naoki Inoue
Summary: The compound 147B3 has shown efficacy in inhibiting HCMV and HSV-1 infection, potentially by targeting viral transactivators through their interaction with factors required for the viral gene expression system.
ANTIVIRAL RESEARCH
(2021)
Article
Microbiology
Xiaomin Guo, Yanxing An, Wanmin Tan, Ling Ma, Mingyang Wang, Juyan Li, Binghong Li, Wei Hou, Li Wu
Summary: The antiviral peptide WL-1 derived from human cathelicidin has been shown to inhibit herpes simplex virus 1 (HSV-1) infection and improve host survival, reduce viral load and inflammation. It also prevents the occurrence of facial palsy in HSV-1-infected mice.
FRONTIERS IN MICROBIOLOGY
(2023)
